Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability and efficacy of 3 doses of vernakalant (oral) (150 mg,
300 mg and 500 mg b.i.d.) administered for up to 90 days in subjects with sustained
symptomatic atrial fibrillation (AF duration > 72 hours and < 6 months).